A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella

Manlio Fusciello, Erkko Ylösmäki*, Sara Feola, Arttu Uoti, Beatriz Martins, Karri Aalto, Firas Hamdan, Jacopo Chiaro, Salvatore Russo, Tapani Viitala, Vincenzo Cerullo*

*Corresponding author for this work

Research output: Contribution to journalArticleScientificpeer-review

1 Citation (Scopus)

Abstract

Common vaccines for infectious diseases have been repurposed as cancer immunotherapies. The intratumoral administration of these repurposed vaccines can induce immune cell infiltration into the treated tumor. Here, we have used an approved trivalent live attenuated measles, mumps, and rubella (MMR) vaccine in our previously developed PeptiENV cancer vaccine platform. The intratumoral administration of this novel MMR-containing PeptiENV cancer vaccine significantly increased both intratumoral as well as systemic tumor-specific T cell responses. In addition, PeptiENV therapy, in combination with immune checkpoint inhibitor therapy, improved tumor growth control and survival as well as increased the number of mice responsive to immune checkpoint inhibitor therapy. Importantly, mice pre-vaccinated with the MMR vaccine responded equally well, if not better, to the PeptiENV therapy, indicating that pre-existing immunity against the MMR vaccine viruses does not compromise the use of this novel cancer vaccine platform.

Original languageEnglish
Pages (from-to)137-145
Number of pages9
JournalMolecular Therapy - Oncolytics
Volume25
DOIs
Publication statusPublished - 16 Jun 2022
Externally publishedYes
MoE publication typeA1 Journal article-refereed

Keywords

  • cancer vaccines
  • measles
  • mumps
  • oncolytic viruses
  • PeptiENV
  • personalized medicine
  • Priorix
  • rubella

Fingerprint

Dive into the research topics of 'A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella'. Together they form a unique fingerprint.

Cite this